DEB试验也是全球首个在初治、MYC/BCL2双表达弥漫大B细胞淋巴瘤为适应症的III期注册临床研究,旨在评估西达本胺联合R-CHOP对比R-CHOP在初治、MYC/BCL2双表达DLBCL受试者中的有效性和安全性。根据西达本胺联合R-CHOP一线治疗双表达弥漫大B细胞淋巴瘤三期临床试验的期中分析结果,与经典R-CHOP一线治疗方案相比,西达本...
参考文献: [1] U Vitolo , J F Seymour , M Martelli et al. Extranodal Diffuse Large B-cell Lymphoma (DLBCL) and Primary Mediastinal B-cell Lymphoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follo...
弥漫大B细胞淋巴瘤(Diffuse Large B-Cell Lymphoma, DLBCL)是临床最常见的非霍奇金淋巴瘤,60%左右的患者一线免疫化疗(如R-CHOP方案)后都可获得完全缓解和长期无病生存。多年来,R-CHOP一直是DLBCL的标准一线…
股票代码:688321.SH)宣布,由公司自主研发的亚型选择性组蛋白去乙酰化酶(HDAC)口服抑制剂西达本胺联合R-CHOP(利妥昔单抗、环磷酰胺、阿霉素、长春新碱和强的松)用于MYC和BCL2表达阳性的既往未经治疗的弥漫大B细胞淋巴瘤(DLBCL)适应症获得中国国家药品监督管理局(NMPA)正式批准。
背景与目的:根据肿瘤细胞起源不同,可将弥漫大B细胞淋巴瘤(diffuselarge B-cell lymphoma,DLBCL)分为生发中心来源(germinal center B-cell like,GCB)及非生发中心来源(non-GCB)两种亚型。在以CHOP方案为标准的化疗基础上,前者预后优于后者。本研究通过比较R-CHOP(Rituximab联合CHOP)和CHOP方案治疗不同亚型DLBCL患者的...
既然OS生存率data目前还不够sexy,那我们换个角度来看看,在接受过PR-CHP治疗之后再换到下面这些疗法(Subsequent lymphoma treatment was defined as non-protocolanti-lymphoma therapy)继续治疗,这时候两组患者的差别就明显出来了:不管后面患者再接受...
There were no protocol treatment-related deaths, nor were there any fatal infections attributable to subsequent lymphoma treatment. At 15 years, the cumulative incidence of non-haematological and haematological malignancies was 12.8% and 3.7% respectively. Histological transformation appeared after a median...
Could treatment with R‐HCVAD/R‐MA as compared to R‐CHOP truly result in improved outcomes for patients with high‐risk diffuse large B cell lymphoma? Could treatment with R-HCVAD/R-MA as compared to R-CHOP truly result in improved outcomes for patients with high-risk diffuse large B ...
FDA批准Polivy联合R-CHP用于DLBCL的一线治疗是基于POLARIX的关键数据,POLARIX是一项国际III期随机双盲安慰剂对照研究,证明与R-CHOP相比,PFS有统计学意义和临床意义的改善。与R-CHOP相比,Polivy加R-CHP (n=440)的疾病进展、复发或死亡风险降低了27 %。 至于安全性,报告的最常见不良事件包括周围神经病变、恶心、疲劳、...
2024年4月24日,上海交通大学医学院附属瑞金医院赵维莅教授团队《Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III...